Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 208 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Radiopharmaceuticals Clear all
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau Imaging With JNJ067

NCT03926702
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
Interventions
Radiopharmaceuticals
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

NCT01686256
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 12, 2026, 10:36 PM EDT
Completed No phase listed Observational Results available

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

NCT02127307
View directory record Official record
Conditions
Heart Failure (HF)
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG

NCT01730417
View directory record Official record
Conditions
Neuroendocrine Tumors, Heart Failure
Interventions
no carrier added metaiodobenzylguanidine
Drug
Lead sponsor
Bennett Chin
Other
Eligibility
21 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiac Water and Fluoromethane Cardiac PET

NCT00205127
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cardiac PET imaging- rest and pharmacological stress
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2012 · Synced Sep 12, 2026, 10:36 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed No phase listed Observational

Positron Emission Tomography in Patients With Breast Cancer

NCT00001385
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

NCT04237584
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Enzalutamide during Lead-in Period, Lead-in Enzalutamide followed by Radium-223/Enzalutamide, Lead-in Enzalutamide followed by Placebo/Enzalutamide, Darolutamide during Lead-in Period, Lead-in Darolutamide followed by Radium-223/Darolutamide, Lead-in Darolutamide followed by Placebo/Darolutamide
Drug
Lead sponsor
MANA RBM
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Phase 1 Interventional

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

NCT07165132
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor, Somatostatin Receptor
Interventions
RYZ401
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
7
States / cities
Iowa City, Iowa • Lexington, Kentucky • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Interventions
Lutetium [177Lu] oxodotreotide/dotatate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
3
States / cities
Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

NCT06726161
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
RYZ811, RYZ801
Diagnostic Test · Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Phase 1 Interventional

Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain

NCT07197645
View directory record Official record
Conditions
Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
Interventions
153Sm-DOTMP
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Phase 3 Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414
View directory record Official record
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Early Phase 1 Interventional

In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

NCT03492164
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
[18F]FluorThanatrace ([18F]FTT)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting Phase 1 Interventional

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT07581184
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3
Interventions
[225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
Drug
Lead sponsor
Aktis Oncology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Irvine, California • Miami, Florida • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Image-Guided Stereotactic Biopsy of High Grade Gliomas

NCT00979810
View directory record Official record
Conditions
Brain Cancer, Glioma
Interventions
18F-FLT PET Scan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 89 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

NCT04069429
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Computerized Tomography scan, Single Photon Emission Computed Tomography scans, Technetium Tc 99M, Planar Images, Esophagogastroduodenoscopy
Radiation · Drug · Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 12, 2026, 10:36 PM EDT
Recruiting No phase listed Observational

PET/MR for Characterization of Renal Masses (RMs)

NCT06076538
View directory record Official record
Conditions
Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions
2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 12, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli

NCT00519506
View directory record Official record
Conditions
Acute Pulmonary Embolism
Interventions
ThromboView
Other
Lead sponsor
Agen Biomedical
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Sacramento, California • San Diego, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2009 · Synced Sep 12, 2026, 10:36 PM EDT
Terminated Phase 1 Interventional

PET Imaging of Intracranial Cancers With 18F-FSPG

NCT02370563
View directory record Official record
Conditions
Brain Cancer
Interventions
18F-FSPG
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 12, 2026, 10:36 PM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias

NCT04786223
View directory record Official record
Conditions
Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Interventions
C-11 ER-176, Blood Test
Drug · Diagnostic Test
Lead sponsor
Val Lowe
Other
Eligibility
60 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 12, 2026, 10:36 PM EDT